
ANL Stock Forecast & Price Target
ANL Analyst Ratings
Bulls say
Adlai Nortye is building a promising pipeline of drug candidates with a focus on RAS-targeting therapies and next-generation cancer immunotherapies. With its differentiated approach of localizing panRAS inhibition and its competitive pre-clinical profile, coupled with the potential for intermittent dosing and combination therapy, AN9025 has the potential to become a best-in-class panRAS inhibitor and carve out a sizable market share in RAS-driven cancers. Furthermore, Adlai Nortye's modest valuation compared to its competitors and the potential for global deals and development partnerships add to the upside potential of this stock.
Bears say
Adlai Nortye is a clinical-stage company with a negative outlook, as its AN9025 panRAS inhibitor faces potential toxicity issues due to its higher affinity and longer half-life. The company has not yet generated revenue, making it dependent on the successful commercialization of its current candidates to achieve profitability. However, AN9025's potential intermittent dosing and AN4035's localized delivery are promising differentiators from other RAS-targeting therapies. Despite these potential advantages, the company's clinical validation, pipeline failures, and liquidity risk could delay its time to profitability.
This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.
ANL Analyst Forecast & Price Prediction
Start investing in ANL
Order type
Buy in
Order amount
Est. shares
0 shares